{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.98","upperLimit":"2.17","value":"2.00"},{"groupId":"OG001","lowerLimit":"1.83","upperLimit":"164","value":"2.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Tmax was defined as the time (in hours) to achieve Cmax (Cmax was defined as the highest serum concentration observed over all sample collection timepoints \\[as provided in timeframe\\]). The median time, among all participants, was reported.","dispersionType":"Full Range","groups":[{"description":"Participants received MIRCERA IV injection at a starting dose based on an intermediate conversion factor from their previous ESA dose (4 \\* previous weekly epoetin dose \\[IU\\]/250 or 4 \\* previous weekly darbepoetin alfa dose \\[mcg\\]/1.1) once every 4 weeks for 20 weeks. Participants who completed the 20 weeks of treatment and had Hb level within ± 1 g/dL of their baseline Hb level and within the target range of 10-12 g/dL, entered an optional 52-weeks safety extension period. During this period, the participants continued to receive MIRCERA IV injection once every 4 weeks.","id":"OG000","title":"MIRCERA Group 1: Intermediate-Conversion-Factor Group"},{"description":"Participants received MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 \\* previous weekly epoetin dose \\[IU\\]/125 or 4 \\* previous weekly darbepoetin alfa dose \\[mcg\\]/0.55) once every 4 weeks for 20 weeks. Participants who completed the 20 weeks of treatment and had Hb level within ± 1 g/dL of their baseline Hb level and within the target range of 10-12 g/dL, entered an optional 52-weeks safety extension period. During this period, the participants continued to receive MIRCERA IV injection once every 4 weeks.","id":"OG001","title":"MIRCERA Group 2: High-Conversion-Factor Group"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population.","reportingStatus":"POSTED","timeFrame":"Pre-dose (with 1 hour before drug administration) and 2, 48 hours post dose on Week 9, at Weeks 10, 11, and 12, pre-dose (with 1 hour before drug administration) on Week 13","title":"Time to Reach Cmax (Tmax) of MIRCERA","type":"SECONDARY","unitOfMeasure":"hours"}